DOCSLIB.ORG

Analytical Reference Standards 2021 / 02 (V3)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

SERVICES TO HEALTH Analytical Reference Standards 2021 / 02 (v3) 1 Analytical SERVICES TO HEALTH Reference Standards Website Newsletter For information about LIPOMED’s To be updated on the release Reference Standards and about of new products, please request our new products continuously our newsletter by subscribing at: added to our product range, [email protected]. please visit www.lipomed.com. 2 Analytical SERVICES TO HEALTH Reference Standards NEW WEBSHOP USA /CH /DE /FR New Webshop LIPOMED will progressively expand its new webshop to simplify online ordering and the process of requesting quotes. www.lipomed-shop.com www.lipomed-usa.com 3 Analytical SERVICES TO HEALTH Reference Standards Table of Contents Company Profile ����������������������������������������������������������������������������������������� 5 Analytical Reference Standards . 7 Why choose LIPOMED Reference Standards . 12 Commitment to Quality ��������������������������������������������������������������������������� 13 Certificate of Analysis ������������������������������������������������������������������������������� 18 Tandem Mass Spectra Database ����������������������������������������������������������� 26 Contact Information . 28 Catalog User Guide ��������������������������������������������������������������������������������� 34 Aqueous Ethanol Standard Solutions ����������������������������������������������������� 35 Alphabetical Product List ������������������������������������������������������������������������� 36 Alphabetical Index. 254 Catalog Number Index . 263 Substance Class Index . 271 Standard Terms and Conditions of Sale ����������������������������������������������� 279 4 Analytical SERVICES TO HEALTH Reference Standards Company Profile LIPOMED is a private owned of Analytical Reference Standards research and development based and ISO 17034 (ANAB Certificate Health Care Company that No. AR-1761) accredited for serves the worldwide market for Reference Material production. Pharmaceuticals and Reference All products distributed by Standards. The headquarters is LIPOMED affiliates are manu- located in Arlesheim near Basel, factured by LIPOMED AG and Switzerland. distributed under protocols of LIPOMED AG. LIPOMED AG, Switzerland is GMP/GDP and ISO 9001 certified Additionally, the Pharma for production and distribution Marketing of LIPOMED is certified of Pharmaceuticals and according to the "Référentiel de ISO/IEC 17025 (ANAB Certificate certification de la visite médicale" No. AT-1760) accredited for testing by the French Authorities. 5 Analytical SERVICES TO HEALTH Reference Standards LIPOMED Inc. in Cambridge, Massachusetts, USA Lipomed Inc. is the distributor of our reference standards in North, Central and South America plus the Caribbean (except: Curaçao, Columbia, Argentina). LIPOMED GmbH in Weil am Rhein, Germany LIPOMED GmbH serves as a logistic and distribution center for Reference Standards and Pharmaceuticals in Germany. LIPOMED GmbH is also the Marketing Authorization Holder for the pharmaceutical products in Europe. It is ISO 9001 certified. 6 Analytical SERVICES TO HEALTH Reference Standards Analytical Reference Standards LPOMED is a leading producer and analytical techniques, LIPOMED supplier of Analytical Reference reference standards are available Materials manufactured according as calibrated ready-to-use (RTU) to the highest quality standards solutions as well as powders. currently given to reference This has been done to provide materials producers. Indeed, our customers additional flexibility LIPOMED holds ISO/IEC 17025 in choosing the most appropriate (ANAB certificate no. AT-1760) and form for their needs. ISO 17034 (ANAB certificate no. AR-1761) accreditations as well Our range of product offering as ISO 9001 certification to meet is continuously expanding in customers’ expectations for quality order to assist our customers and reliability. in providing the highest quality reference materials they need to LIPOMED reference standards perform their analysis. If you do currently include the following not find the product(s) you are classes of substances, their looking for please contact us. deuterated analogues and metabolites there of: For information about LIPOMED’s new Reference Standards, • Amphetamines & please visit www.lipomed.com. sympathomimetic amines • Antidepressants LIPOMED’s reference standards • Antipsychotics are available worldwide either • Aqueous ethanol standards through LIPOMED offices in • Barbiturates Europe and in the USA, and • Benzodiazepines through a selected network of • Cannabinoids appointed distributors for local • Cathinones customer services. Please see • Certified Reference Materials page 28 for LIPOMED offices and (CRMs) page 29 till page 33 for LIPOMED’s • CNS depressants appointed distributors or visit • Cocaines www.lipomed.com. • Custom mixtures • Designer drugs All reference standards distributed • Ethanol biomarkers by LIPOMED Inc. and by any other • Hallucinogens affiliate or partner company • Opioids under the LIPOMED label are • Steroids manufactured by the ISO certified • Vitamins company LIPOMED AG. Supplied as native and stable- isotope labeled for mass spectrometry and other 7 Analytical SERVICES TO HEALTH Reference Standards Transfer Labels LIPOMED progressively introduces providing safe and accurate calibrated ampoules with labels identification of vials used to store that can easily be transferred our calibrated reference standard from an ampoule to e. g. auto solutions after original ampoules sampler vials. This innovative are opened. feature supports customers in 8 Analytical SERVICES TO HEALTH Reference Standards Solutions and Powders available RTU Solutions are intended for LIPOMED’s Reference Standards quantitative ready-to-use purposes. are available as powders and Accurate strength is based on the as calibrated ready-to-use (RTU) free drug substance. solutions. LIPOMED’s Reference Standards are also available as powders in standard pack sizes of 10 mg, 50 mg and 100 mg. Larger quantities might be available upon request. The weight is based on the drug substance. RTU Solution Reference target volume of 1 ml can be Standards quantitatively transferred. LIPOMED’s 1mg/ml and 0.1 mg/ml RTU solutions offer many ampoules contain high precision advantages over powders such calibrated reference standards as accuracy in the provided to an accuracy of 1.000 ± solution strengths, enhanced 0.050 mg/ml and 0.100 ± consistency from lot to lot, and 0.005 mg/ml of free drug convenience of use, especially substance in sealed amber glass when used in routine testing. ampoules under argon for added stability. LIPOMED’s ampoules are over-filled to ensure that the 9 Analytical SERVICES TO HEALTH Reference Standards Manufacturing Aside from classical synthesis in batch reactors LIPOMED produces Reference Standards using Microflow Technology which guarantees unrivaled lot-to-lot identity and unmatched product purity. Ampoule Filling Lines Our calibrated solutions are produced in LIPOMED’s own ampoule filling lines to ensure batch-to-batch consistency and reproducibility. Analytical Quality Control calibrated solution, as well as for All our products in powder are each bulk powder. systematically analyzed in-house to ensure the identity and the LIPOMED is also providing its purity of our reference standards. reference standards solutions IR, UV, melting point, MS, Proton as Certified Reference Materials NMR are used to confirm the (CRMs) according to ISO/IEC identity of the products and HPLC, 17025 and ISO 17034 guidelines. GC, LC/MS or HPTLC CAMAG are Ampoules are analyzed to ensure used to monitor the chemical a level of confidence of 95 % and and isotopic purity of our stability data are performed on reference standards. each product (non-deuterated and deuterated). A lot specific certificate of analysis is available for each 10 Analytical SERVICES TO HEALTH Reference Standards Shelf life Retest and expiry dates should Stability monitoring is performed be read as per end of the stated on all Reference Standards at month. appropriate intervals. Storage For most of LIPOMED’s Reference Airtight storage at a temperature Standards, retest dates are of 2 – 8 °C in a dark location is provided on the Certificates recommended, unless otherwise of Analysis (COA) together indicated on the label and in the with the corresponding batch COA. numbers. Retests are performed by LIPOMED 6 months prior to the Use stated retest dates. This allows for LIPOMED Reference Standards a validity extension of the retested are not qualified for administration batch subject to successful retest, in humans or animals. In addition, proper storage and unopened our Reference Standards are ampoules/vials. not qualified against official Pharmacopoeia Reference Updated COA are available Standards. Therefore GLP, GCP or on the website or by e-mail: GMP applications are under the [email protected] (North, full responsibility of the end user. Central and South America plus the Caribbean, except: Curaçao, Safety Columbia, Argentina) and All products mentioned in this [email protected] (all other catalog have to be considered countries). potentially toxic substances and must be handled by suitably trained staff. 11 Analytical SERVICES TO HEALTH Reference Standards Why choose LIPOMED Reference Standards • Privately owned with 25 Years • Special products available of Consistency, Quality, and such as alcohol biomarkers, Precision custom mixtures, designer drugs, opiates glucuronides, • Pharmaceutical
Recommended publications
  • Anabolic Steroid Use Misuse and Addiction

    Anabolic Steroid Use Misuse and Addiction

    Anabolic Steroid Use, Misuse And Addiction JASSIN M. JOURIA Dr. Jassin M. Jouria is a medical doctor, professor of academic medicine, and medical author. He graduated from Ross University School of Medicine and has completed his clinical clerkship training in various teaching hospitals throughout New York, including King’s County Hospital Center and Brookdale Medical Center, among others. Dr. Jouria has passed all USMLE medical board exams, and has served as a test prep tutor and instructor for Kaplan. He has developed several medical courses and curricula for a variety of educational institutions. Dr. Jouria has also served on multiple levels in the academic field including faculty member and Department Chair. Dr. Jouria continues to serve as a Subject Matter Expert for several continuing education organizations covering multiple basic medical sciences. He has also developed several continuing medical education courses covering various topics in clinical medicine. Recently, Dr. Jouria has been contracted by the University of Miami/Jackson Memorial Hospital’s Department of Surgery to develop an e-module training series for trauma patient management. Dr. Jouria is currently authoring an academic textbook on Human Anatomy & Physiology. ABSTRACT The synthetic versions of the male hormone testosterone, also known as anabolic steroids, can play an important role in the treatment of health conditions when used as prescribed by a medical clinician. However, misuse of anabolic steroids occurs when these substances are used solely to improve physical appearance or performance. Because there are some potentially serious physical effects of anabolic steroid use, it is important that anabolic steroids are only used as prescribed and always under a medical clinician’s guidance.
  • Endogenous Metabolites: JHU NIMH Center Page 1

    Endogenous Metabolites: JHU NIMH Center Page 1

    S. No. Amino Acids (AA) 24 L-Homocysteic acid 1 Glutaric acid 25 L-Kynurenine 2 Glycine 26 N-Acetyl-Aspartic acid 3 L-arginine 27 N-Acetyl-L-alanine 4 L-Aspartic acid 28 N-Acetyl-L-phenylalanine 5 L-Glutamine 29 N-Acetylneuraminic acid 6 L-Histidine 30 N-Methyl-L-lysine 7 L-Isoleucine 31 N-Methyl-L-proline 8 L-Leucine 32 NN-Dimethyl Arginine 9 L-Lysine 33 Norepinephrine 10 L-Methionine 34 Phenylacetyl-L-glutamine 11 L-Phenylalanine 35 Pyroglutamic acid 12 L-Proline 36 Sarcosine 13 L-Serine 37 Serotonin 14 L-Tryptophan 38 Stachydrine 15 L-Tyrosine 39 Taurine 40 Urea S. No. AA Metabolites and Conjugates 1 1-Methyl-L-histidine S. No. Carnitine conjugates 2 2-Methyl-N-(4-Methylphenyl)alanine 1 Acetyl-L-carnitine 3 3-Methylindole 2 Butyrylcarnitine 4 3-Methyl-L-histidine 3 Decanoyl-L-carnitine 5 4-Aminohippuric acid 4 Isovalerylcarnitine 6 5-Hydroxylysine 5 Lauroyl-L-carnitine 7 5-Hydroxymethyluracil 6 L-Glutarylcarnitine 8 Alpha-Aspartyl-lysine 7 Linoleoylcarnitine 9 Argininosuccinic acid 8 L-Propionylcarnitine 10 Betaine 9 Myristoyl-L-carnitine 11 Betonicine 10 Octanoylcarnitine 12 Carnitine 11 Oleoyl-L-carnitine 13 Creatine 12 Palmitoyl-L-carnitine 14 Creatinine 13 Stearoyl-L-carnitine 15 Dimethylglycine 16 Dopamine S. No. Krebs Cycle 17 Epinephrine 1 Aconitate 18 Hippuric acid 2 Citrate 19 Homo-L-arginine 3 Ketoglutarate 20 Hydroxykynurenine 4 Malate 21 Indolelactic acid 5 Oxalo acetate 22 L-Alloisoleucine 6 Succinate 23 L-Citrulline 24 L-Cysteine-glutathione disulfide Semi-quantitative analysis of endogenous metabolites: JHU NIMH Center Page 1 25 L-Glutathione, reduced Table 1: Semi-quantitative analysis of endogenous molecules and their derivatives by Liquid Chromatography- Mass Spectrometry (LC-TripleTOF “or” LC-QTRAP).
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
  • Anabolic Androgenic Steroid Use Prevalence, Knowledge, and Practice Among Male Athletes in Eastern Province of Saudi Arabia

    Anabolic Androgenic Steroid Use Prevalence, Knowledge, and Practice Among Male Athletes in Eastern Province of Saudi Arabia

    Electronic Journal of General Medicine 2020, 17(2), em187 e-ISSN: 2516-3507 https://www.ejgm.co.uk/ Original Article OPEN ACCESS Anabolic Androgenic Steroid Use Prevalence, Knowledge, and Practice among Male Athletes in Eastern Province of Saudi Arabia Huda Hassan Aldarweesh 1, Alyaa Hassan Alhajjaj 1* 1 Qatif Central Hospital, SAUDI ARABIA *Corresponding Author: [email protected] Citation: Aldarweesh HH, AlHajjaj AH. Anabolic Androgenic Steroid Use Prevalence, Knowledge, and Practice among Male Athletes in Eastern Province of Saudi Arabia. Electron J Gen Med. 2020;17(2):em187. https://doi.org/10.29333/ejgm/7617 ARTICLE INFO ABSTRACT Received: 25 Oct. 2019 Background: Anabolic androgenic steroids (AAS) are synthetic testosterone like hormones. AAS usage by athletes Accepted: 30 Dec. 2019 has increased dramatically over the past decade. Material and Methods: This study was designed to examine the prevalence, attitude and awareness of AAS abuse among athletes n the Eastern province of Saud Arabia. This was a cross-sectional survey that was conducted among male athletes attending twenty fitness centres in the Eastern Province. It was done during the period from April to August, 2018. Results: A total of 573 questionnaires were distributed but only 503 participants were included n the final analysis. The frequency of AAS use was 17.69%. The man reason for AAS use was muscle building (68.54%). The man source of AAS was the coaches. 56.18% of the users recognize the harmful effects of AAS. The most commonly used oral AAS form was oxandrolone (61.80%). The most commonly used substance for post cycle therapy was Tamoxifen citrate n 67.42% of the users.
  • Metabolism of Anabolic Steroids in Man: Synthesis and Use of Reference Substances for Identification of Anabolic Steroid Metabolites

    Metabolism of Anabolic Steroids in Man: Synthesis and Use of Reference Substances for Identification of Anabolic Steroid Metabolites

    Anaiytzca Chumca Acta, 275 (1993) 23-48 23 Elsevler hence Publishers B V , Amsterdam Metabolism of anabolic steroids in man: synthesis and use of reference substances for identification of anabolic steroid metabolites Will1 Schanxer and Manfred Domke LkutscheS’rthochschuk Koln, Inrhtut f?u Bwchemre, Carl-L&m-Weg 4 5ooO Cologne 41 (Germuny) (Recewed 20th May 1992) AhStl-& The use of anabohc steroids was banned by the International Olympic Comnuttee for the first tune at the Olympic Games m Montreal m 1976 Since that tie the nususe of anabohc steroxls by athletes has been controlled by analysis of urme extracts by gas chromatography-mass spectrometry @C-MS) The excreted steroids or their metabohtes, or both, are isolated from urme by XAD-2 adsorption, enzymatx hydrolyss of coqlugated excreted metabobtes anth /?-glucuromdase from Es&en&u co& bqmd-bqmd extractlon mth diethyl ether, and courted mto tnmethylsdyl (‘INiS) derwatwes The confirmation of an anabobc stenxd nususe ts based on comparison of the electron nnpact lomzation (EI) mass spectrum and GC retention tie of the isolated steroid and/or its metabohte with the El mass spectrum and GC retention time of authentic reference substances For this purpose excretion studies with the most common anabobc steroids were performed and the mam excreted metabobtes were synthesued for bolasterone, boldenone, 4-chiorodehydromethyltestosterone, clostebol, drostanolone, tluoxymesterone, forme- bolone, me&a&one, mesterolone, metandlenone, methandnol, metenolone, methyltestosterone, nandrolone, norethandrolone,
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
  • Megestrol Acetate/Melengestrol Acetate 2115 Adverse Effects and Precautions Megestrol Acetate Is Also Used in the Treatment of Ano- 16

    Megestrol Acetate/Melengestrol Acetate 2115 Adverse Effects and Precautions Megestrol Acetate Is Also Used in the Treatment of Ano- 16

    Megestrol Acetate/Melengestrol Acetate 2115 Adverse Effects and Precautions Megestrol acetate is also used in the treatment of ano- 16. Mwamburi DM, et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar As for progestogens in general (see Progesterone, rexia and cachexia (see below) in patients with cancer results in 2 months. Clin Infect Dis 2004; 38: 895–902. p.2125). The weight gain that may occur with meges- or AIDS. The usual dose is 400 to 800 mg daily, as tab- 17. Grunfeld C, et al. Oxandrolone in the treatment of HIV-associ- ated weight loss in men: a randomized, double-blind, placebo- trol acetate appears to be associated with an increased lets or oral suspension. A suspension of megestrol ace- controlled study. J Acquir Immune Defic Syndr 2006; 41: appetite and food intake rather than with fluid reten- tate that has an increased bioavailability is also availa- 304–14. tion. Megestrol acetate may have glucocorticoid ef- ble (Megace ES; Par Pharmaceutical, USA) and is Hot flushes. Megestrol has been used to treat hot flushes in fects when given long term. given in a dose of 625 mg in 5 mL daily for anorexia, women with breast cancer (to avoid the potentially tumour-stim- cachexia, or unexplained significant weight loss in pa- ulating effects of an oestrogen—see Malignant Neoplasms, un- Effects on carbohydrate metabolism. Megestrol therapy der Precautions of HRT, p.2075), as well as in men with hot 1-3 4 tients with AIDS. has been associated with hyperglycaemia or diabetes mellitus flushes after orchidectomy or anti-androgen therapy for prostate in AIDS patients being treated for cachexia.
  • Pharmacy and Poisons Act 1979

    Pharmacy and Poisons Act 1979

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS ACT 1979 1979 : 26 TABLE OF CONTENTS PART I PRELIMINARY 1 Short title 2 Interpretation PART II THE PHARMACY COUNCIL 3 The Pharmacy Council 4 Membership of the Council 4A Functions of the Council 4B Protection from personal liability 4C Annual Report 5 Proceedings of the Council, etc PART III REGISTRATION OF PHARMACISTS 6 Offence to practise pharmacy if not registered 7 Registration as a pharmacist 7A Re-registration as non-practising member 7AA Period of validity of registration 8 Code of Conduct 9 Pharmacy Profession Complaints Committee 10 Investigation of complaint by Committee 10A Inquiry into complaint by Council 10B Inquiry by Council of its own initiative 11 Surrender of registration 12 Restoration of name to register 1 PHARMACY AND POISONS ACT 1979 13 Proof of registration 14 Appeals 14A Fees 14B Amendment of Seventh Schedule 15 Regulations for this part PART IV REGISTRATION OF PHARMACIES 16 Register of pharmacies 17 Registration of premises as registered pharmacies 18 Unfit premises: new applications 19 Unfit premises: registered pharmacies 20 Appeals 21 When certificates of unfitness take effect 22 Regulations for this Part PART V CONTROL OF PRESCRIPTIONS AND IMPORTATION 23 Prescriptions to be in a certain form 23A Validity of a prescription 24 Supply by registered pharmacist of equivalent medicines 25 Restrictions on the importation of medicines 26 Declaration relating to imported medicines [repealed] PART VI CONTROL OF DRUGS 27 Certain substances to be sold on prescription
  • MMC International BV

    MMC International BV

    M.M.C. International Steroid Substances Steroid Test A Colour Steroid Test B Colour Steroid Test B Colour with UV Light Stanozolol/ Oxandrolone Test Clenbuterol/ Oxymetholone Test Ephedrine Test Alfadolone Orange Yellow Nil - - - Androsterone Orange Yellow White - - - Beclometasone Brown–yellow Orange Nil - - - Betamethasone Orange–brown Pink–Orange Nil - - - Boldenone Base (Equipoise, Ganabol) (pure powder) Warm red after 2 min. Dark Orange after 2 min. Bright Light Orange - - - Boldenone Undecanoate (oil) Dark brownish-red Dark Red Bright Light Orange - - - Boldenone Undecylenate (oil) Orange - Light Brown Dark Orange → Brown Bright Light Orange-Yellow - - - Carbenoxolone (CBX) Orange Yellow Yellow - - - Cholesterol Violet Orange White - - - Clenbuterol (Spiropent, Ventipulmin) - - - - Purple - Dark brown with yellow-green on the Dark brown with yellow-green on the Clomiphene (Androxal, Clomid, Omifin) Nil Dark brown to black No reaction Dark brown to black sides of the ampoule sides of the ampoule Cortisone Orange Yellow Green - - - Desoxycortone Blue–black Yellow Yellow - - - Dexamethasone Yellow Orange–pink Nil - - - Dienestrol Yellow Orange–red Nil - - - Diethylstilbestrol (DES) Orange (→yellow–green) Nil - - - Dimethisterone Brown–green Orange–red Yellow - - - Drostanolone Propionate (Masteron) (oil) Bright green Yellow-Orange Orange - - - Dydrogesterone (Duphaston) - Orange Green-Yellow - - - Enoxolone Orange Yellow Green-Yellow - - - Ephedrine (also for Pseudo- and Nor-Ephedrine) - - - - - Orange Estradiol (Oestradiol) Orange
  • University of Groningen Multi-Residue Analysis of Growth Promotors In

    University of Groningen Multi-Residue Analysis of Growth Promotors In

    University of Groningen Multi-residue analysis of growth promotors in food-producing animals Koole, Anneke IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 1998 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Koole, A. (1998). Multi-residue analysis of growth promotors in food-producing animals. s.n. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 25-09-2021 APPENDIX 1 OVERVIEW OF RELEVANT SUBSTANCES This appendix consists of two parts. First, substances that are relevant for the research presented in this thesis are given. For each substance CAS number (CAS), molecular weight (MW), bruto formula (formula) and if available UV maxima and alternative names are given. In addition, pKa values for the ß-agonists are listed, if they were available.
  • Presented to the Graduate Council of the University of North Texas in Partial Fulfillment of the Requirements for the Degree Of

    Presented to the Graduate Council of the University of North Texas in Partial Fulfillment of the Requirements for the Degree Of

    3-7? CHEMICAL IONIZATION (CI) GC/MS ANALYSIS OF UNDERIVATIZED AMPHETAMINES FOLLOWED BY CHIRAL DERIVATIZATION TO IDENTIFY d AND 1-ISOMERS WITH ION TRAP MASS SPECTROMETRY THESIS Presented to the Graduate Council of the University of North Texas in Partial Fulfillment of the Requirements for the Degree of MASTER OF SCIENCE (Pharmacology) By John A. Tarver B.S.,B.A. May, 1991 Tarver, John A. Chemical Ionization (CI) GC/MS Analysis of Underivatized Amphetamines Followed by Chiral Derivatiza- tion to Identify d and 1-Isomers with Ion Trap Mass Spectro- metry. Master of Science (Biomedical Sciences), May, 1991, 26 pp., 9 figures, bibliography, 20 titles. An efficient two step procedure has been developed using CI GC/MS for analyzing amphetamines and related compounds. The first step allows the analysis of underiv- atized amphetamines with the necessary sensitivity and specificity to give spectral identification, including differentiation between methamphetamine and phentermine. The second step involves preparing a chiral derivative of the extract to identify d and 1-isomeric composition. TABLE OF CONTENTS Page LIST OF ILLUSTRATIONS.......... ... .. .. .......... iv INTRODUCTION .1........................... EXPERIMENTAL MATERIALS ...--- - - - - ----... -....-..... 15 METHODS --------------------.---...... 15 RESULTS AND DISCUSSION ...-..-..................... 17 CONCLUSION - - - - - -- - - - - --- - --- . - . 23 APPENDIX......... ---. -----....-.-. ----.. -........ 24 REFERENCES ----------------------------.. --. ...---.. 28 iii LIST OF ILLUSTRATIONS
  • 有限公司 Testosterones

    有限公司 Testosterones

    ® 伊域化學藥業（香港）有限公司 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD Rm 1006, 10/F, Hewlett Centre, Tel: (852) 25412772 (4 lines) No. 52-54, Hoi Yuen Road, Fax: (852) 25423444 / 25420530 / 21912858 Kwun Tong, E-mail: [email protected] YICK -VIC 伊域 Kowloon, Hong Kong. Site: http://www.yickvic.com Testosterones Product Code CAS Product Name MIS-42658 1043-10-3 (8S,9S,10R,11S,13S,14S,17S)-11,17-DIHYDROXY-10,13,17-TRIMETHYL-2,6,7,8,9,11,12,14,15,16-DECAHYDRO-1H-CYCLOPENTA[A]PHENA NTHREN-3-ONE UNIE-13864 564-35-2 11-KETOTESTOSTERONE PH-1081U 17-ALPHA-HYDROXYTESTOSTERONE ACETATE MIS-39218 51154-09-7 17ALPHA-METHYLTESTOSTERONE 4,5-EPOXIDE PH-1121 72-63-9 17BETA-HYDROXY-17-METHYLANDROSTA-1,4-DIEN-3-ONE MIS-34565 5585-85-3 17BETA-HYDROXY-17-METHYLANDROSTA-4,6-DIEN-3-ONE PH-1081S 17BETA-HYDROXYANDROST-1-ENE-3-ONE TETRAHYDROPYRANYL ETHER PH-1081VA 1-TESTOSTERONE ETHYL CARBONATE PH-1081VB 1-TESTOSTERONE METHYL CARBONATE PH-1081VC 1-TESTOSTERONE PROPYL CARBONATE PH-1081HB 1-TESTOSTERONE UNDECANOATE UNIE-15172 2141-17-5 4-HYDROXYTESTOSTERONE UNIE-13597 62-99-7 6BETA-HYDROXYTESTOSTERONE SPI-4361 14531-84-1 6-DEHYDRO-19-NORTESTOSTERONE PH-1081PK 1057-07-4 ANDROSTANOLONE 17-BENZOATE Copyright © 2018 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Page 1 of 3 Product Code CAS Product Name PH-1133 1605-89-6 BOLASTERONE UNIE-8525 CHLORDEHYDROMETHYLTESTOSTERONE PH-1081JA 1093-58-9 CLOSTEBOL PH-1081JB 855-19-6 CLOSTEBOL ACETATE SPI-0027GA 481-30-1 EPITESTOSTERONE SPI-0027GB EPITESTOSTERONE ACETATE PH-1081K 434-03-7 ETHISTERONE PH-1136B 76-43-7